Luis Fernando Q. P.
- Country
- Spain
- Department
- 3404: Nefrología
Research Overview
- Effect of Zigakibart on Histologic, Circulating, and Excreted Markers of Kidney Disease and Dysfunction in Adults with IgA Nephropathy: An Open-Label Study
- A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis (IC-MPGN)
- Evaluation of Iptacopan in Combination with Standard-of-Care for Efficacy and Safety in Adult Patients with Active Lupus Nephritis Class III-IV, +/- V
Data & Insights
Has run more than one trial at 51 of 109 partner sites.
Specializations
Glomerular Diseases
This investigator specializes in various forms of glomerulonephritis, with particular focus on focal segmental glomerulosclerosis (FSGS) and membranoproliferative glomerulonephritis. Their research extends to novel therapeutic approaches for these conditions.
- Primary FSGS treatment evaluation
- IC-MPGN therapeutic interventions
- C3 Glomerulopathy management
Autoimmune Kidney Disorders
The investigator conducts research in autoimmune renal conditions, with specific attention to lupus nephritis and IgA nephropathy. Their work includes evaluation of innovative therapeutic agents for these conditions.
- Lupus nephritis Class III-IV treatment
- IgA nephropathy interventions
- Anti-GBM antibody disease therapy
Rare Kidney Disorders
Their expertise extends to rare kidney conditions, including atypical Hemolytic Uremic Syndrome (aHUS) and Goodpasture disease. The research focuses on evaluating novel therapeutic approaches for these challenging conditions.
- aHUS treatment development
- Complement inhibitor therapy
- Anti-GBM disease management
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.